This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sealy, R.
Right arrow Articles by Hurwitz, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sealy, R.
Right arrow Articles by Hurwitz, J. L.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, April 2008, p. 713-719, Vol. 15, No. 4
1071-412X/08/$08.00+0     doi:10.1128/CVI.00412-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Target Peptide Sequence within Infectious Human Immunodeficiency Virus Type 1 Does Not Ensure Envelope-Specific T-Helper Cell Reactivation: Influences of Cysteine Protease and Gamma Interferon-Induced Thiol Reductase Activities{triangledown}

Robert Sealy,1 Wendy Chaka,1 Sherri Surman,1 Scott A. Brown,2 Peter Cresswell,3 and Julia L. Hurwitz1,4*

Departments of Infectious Diseases,1 Immunology, St. Jude Children's Research Hospital, 332 N. Lauderdale St., Memphis, Tennessee 38105,2 Department of Immunobiology, Yale University School of Medicine, HHMI, 300 Cedar St., New Haven, Connecticut 06520,3 Department of Pathology, Health Science Center, University of Tennessee, Memphis, Tennessee, 381634

Received 11 October 2007/ Returned for modification 20 November 2007/ Accepted 21 January 2008

Recent clinical trials have shown that the presence of a robust human immunodeficiency virus type 1 (HIV-1)-specific T-cell response may not be sufficient to prevent or control HIV-1 infection. Studies of antigen processing in the context of infectious HIV-1 are therefore warranted. Envelope-specific, major histocompatibility complex class II-restricted murine T-cell hybridomas were tested for responsiveness to splenic antigen-presenting cells exposed to HIV-1-infected GHOST cells. Interleukin-2 assays showed that the presence of a peptide within HIV-1 did not ensure the reactivation of peptide-specific T cells. Further experiments defined the impact of gamma interferon-induced thiol reductase and cysteine proteases on the processing of HIV-1 peptides. The results highlight potential influences of peptide context on T-cell reactivation by HIV-1 and encourage the continued study of antigen processing as support for improved vaccine design.

* Corresponding author. Mailing address: Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale St., Memphis, TN 38105. Phone: (901) 495-2464. Fax: (901) 495-3107. E-mail: julia.hurwitz{at}stjude.org

{triangledown} Published ahead of print on 30 January 2008.

Clinical and Vaccine Immunology, April 2008, p. 713-719, Vol. 15, No. 4
1071-412X/08/$08.00+0     doi:10.1128/CVI.00412-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»